Fmr LLC Acquires 109,606 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Fmr LLC grew its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 7.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,581,493 shares of the company’s stock after acquiring an additional 109,606 shares during the quarter. Fmr LLC owned 1.75% of Caribou Biosciences worth $3,100,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its holdings in Caribou Biosciences by 16.8% in the second quarter. The Manufacturers Life Insurance Company now owns 36,489 shares of the company’s stock worth $60,000 after purchasing an additional 5,244 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Caribou Biosciences by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock worth $34,000 after buying an additional 6,768 shares during the last quarter. American Century Companies Inc. grew its position in Caribou Biosciences by 15.2% during the second quarter. American Century Companies Inc. now owns 125,029 shares of the company’s stock valued at $205,000 after buying an additional 16,530 shares during the period. AQR Capital Management LLC purchased a new stake in Caribou Biosciences during the second quarter valued at approximately $30,000. Finally, Intech Investment Management LLC bought a new position in Caribou Biosciences in the third quarter worth approximately $43,000. 77.51% of the stock is owned by hedge funds and other institutional investors.

Caribou Biosciences Price Performance

NASDAQ:CRBU opened at $1.91 on Friday. The stock’s 50 day simple moving average is $2.09 and its two-hundred day simple moving average is $2.05. Caribou Biosciences, Inc. has a 1 year low of $1.50 and a 1 year high of $8.33. The company has a market cap of $172.95 million, a price-to-earnings ratio of -1.16 and a beta of 2.27.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. As a group, analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Citigroup reduced their price objective on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a research report on Friday, November 15th. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $10.20.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.